Association between <i>ADCY9</i> Gene Polymorphisms and Ritodrine Treatment Outcomes in Patients with Preterm Labor

• Main Authors: Nari Lee (Author), Ha-Young Yoon (Author), Jin-Young Park (Author), Young-Ju Kim (Author), Han-Sung Hwang (Author), Jeong Yee (Author), Hye-Sun Gwak (Author)
• Format: Book
• Published: MDPI AG, 2021-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

The purpose of this study was to investigate the genetic effects of <i>ADCY9</i> on ritodrine responses in patients with preterm labor. Five single nucleotide polymorphisms (SNPs) of the <i>ADYC9</i> gene in 163 patients in preterm labor were genotyped: rs879619, rs2601796, rs2531988, rs2531995, and rs2230739. Additionally, rs598961 of the <i>PDE4B</i> gene and rs1042719 of the <i>ADRB2</i> gene were included for analysis. Patients with CC genotype of <i>ADCY9</i> rs879619 had a 2.0-fold (95% confidence interval [CI]: 1.3, 3.2) higher hazard of time to delivery than T allele carriers. Patients with combined genotypes of CC in <i>ADCY9</i> rs879619, AA in <i>PDE4B</i> rs598961, and GC, CC in <i>ADRB2</i> rs1042719 showed a greater hazard of time to delivery than patients with other combinations (adjusted hazard ratio [AHR] 3.2; 95% CI: 1.7, 6.3), whereas patients carrying the C allele of <i>ADCY9</i> rs2531995, G allele of <i>PDE4B</i> rs598961, and GG genotype of <i>ADRB2</i> rs1042719 had a lower hazard of time to delivery than patients carrying other genotypes (AHR 0.4; 95% CI: 0.2, 0.7). Regarding ritodrine-induced adverse drug events (ADEs), height less than 160 cm and CC genotype of <i>ADCY9</i> rs2531995 showed a greater risk of ADEs. The results of our study suggest that <i>ADCY9</i> polymorphisms could affect the efficacy and safety of β₂-adrenergic agonists.

Item Description

10.3390/pharmaceutics13101653
1999-4923